Skip to main content

Gabriella Miller Enhanced Delivery Immunotherapy Trial

Project Title

Phase 1 Feasibility Trial of Repeated Convection Enhanced Delivery of HDAC Inhibitor MTX110 (Panobinostat) under real time image guidance for the Treatment of Children with Malignant Midline Gliomas

Layman’s summary

Dr. Mueller hypothesized that treatment options continue to fail for children with malignant midline gliomas because of the blood-brain and blood-tumor barrier. Her first of its kind trial in the U.S. could overcome this by repeated and direct surgical injection of an immunotherapy agent using real-time MRI guidance to ensure medication reaches the tumor.

Sabine Mueller

This Project By The Numbers

  • Years Active
    2 years
  • Amount Awarded
    $100,000.00
  • Institution
    University of California at San Fransisco, Benioff Children’s Hospital

Additional CKc Funded Research